More than 35 million people worldwide live with Type 1 diabetes, relying on continuous glucose monitoring to manage their condition. As diabetes rates rise, the global CGM market is projected to surpass $20 billion by 2032. GluLight is poised to meet this growing demand with a next-generation, light-based solution that delivers accuracy, comfort, and ease of use—unlocking a major opportunity for impact and growth.
$20.2 Billion
by 2032
12.6% CAGR
through 2032
20% of TAM
by 2030
DETAILS ABOUT MARKET
Diabetes is a global epidemic—affecting over 540 million people worldwide. Among them, over 35 million are living with Type 1 diabetes, requiring continuous, accurate glucose monitoring for survival.
The global Continuous Glucose Monitoring (CGM) market is projected to grow from $8.5 billion in 2022 to over $20 billion by 2032, driven by demand for better diabetes care, advancements in technology, and rising healthcare costs.
Market Breakdown (Estimates)
Europe (EU):
• ~9 million people with Type 1 diabetes
• Strong focus on digital health, growing demand for non-invasive CGM solutions
• CE-marked devices enjoy faster adoption
United States (USA):
• ~1.9 million people with Type 1 diabetes
• The largest CGM market globally
• High willingness to adopt smart, app-connected medical technologies
Rest of World (ROW):
• Rapidly growing middle-class populations in Asia and Latin America
• Increasing awareness of diabetes complications and the importance of early intervention
GluLight is strategically positioned to serve these markets with a scalable, user-centric CGM solution—offering real-time monitoring, predictive insights, and reduced healthcare costs.
Wir benötigen Ihre Zustimmung zum Laden der Übersetzungen
Wir nutzen einen Drittanbieter-Service, um den Inhalt der Website zu übersetzen, der möglicherweise Daten über Ihre Aktivitäten sammelt. Bitte überprüfen Sie die Details in der Datenschutzerklärung und akzeptieren Sie den Dienst, um die Übersetzungen zu sehen.